CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
CEGFRR705KPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaGefitinib,ErlotinibLocatelli-Sanchez et al., 2013
BEGFRL858RPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaGefitinibUrata et al., 2016
CEGFRRare MutationPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaGefitinibUrata et al., 2016
DBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinib,Imatinib MesylateBurgess et al., 2005
DBCR::ABL1Fusion AND ABL1 E255KPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinib,Imatinib MesylateBurgess et al., 2005
DBCR::ABL1Fusion AND ABL1 E255KPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinib,Imatinib Mesylate,NilotinibBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib Mesylate,NilotinibBradeen et al., 2006
CVHLR161* (c.481C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseŞahin Atik et al., 2017
CVHLExon 3 DeletionPredisposingN/AVon Hippel-Lindau DiseaseAllasia et al., 2017
DBCR::ABL1Fusion AND ABL1 L248VPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib Mesylate,NilotinibBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 Y253HPredictiveSupportsResistanceChronic Myeloid LeukemiaNilotinib,Imatinib MesylateBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 F311LPredictiveSupportsResistanceChronic Myeloid LeukemiaNilotinib,Imatinib MesylateBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 F359CPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib Mesylate,NilotinibBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 H396PPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib Mesylate,NilotinibBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 V299LPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinib,Imatinib MesylateBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 M244VPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 L248RPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 G250EPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 Q252HPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 D276GPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 V299LPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 F317CPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 F317IPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 F317LPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 F317VPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 M351TPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 E355GPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 F359VPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 V379IPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 H396RPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateBradeen et al., 2006
DAKT3OverexpressionPredictiveSupportsResistanceMelanomaVemurafenibShi et al., 2014
BBRAFAmplification AND ( BRAF V600E OR BRAF V600K )PredictiveSupportsResistanceMelanomaVemurafenib,DabrafenibShi et al., 2014
BNRASMutationPredictiveSupportsResistanceMelanomaVemurafenib,DabrafenibShi et al., 2014
BKRASMutationPredictiveSupportsResistanceMelanomaDabrafenib,VemurafenibShi et al., 2014
DPIK3R2OverexpressionPredictiveDoes Not SupportResistanceMelanomaVemurafenibShi et al., 2014
DBCR::ABL1Fusion AND ABL1 G250EPredictiveSupportsResistanceChronic Myeloid LeukemiaNilotinibBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 F317LPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 Q252HPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibBradeen et al., 2006
DBRAFV600E AND PIK3CA OverexpressionPredictiveSupportsResistanceMelanomaVemurafenibShi et al., 2014
DBCR::ABL1Fusion AND ABL1 E255KPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateBradeen et al., 2006
CVHLN78S (c.233A>G)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseKobayashi et al., 2016
CKRASG13VPredictiveSupportsResistanceColorectal CancerCetuximab,PanitumumabSartore-Bianchi et al., 2009
CKRASG12SPredictiveSupportsResistanceColorectal CancerPanitumumab,CetuximabSartore-Bianchi et al., 2009
CKRASG12DPredictiveSupportsResistanceColorectal CancerPanitumumab,CetuximabSartore-Bianchi et al., 2009
DKRASAmplificationPredictiveSupportsResistanceMelanomaVemurafenibShi et al., 2014
CKRASG12APredictiveSupportsResistanceColorectal CancerPanitumumab,CetuximabSartore-Bianchi et al., 2009
CKRASG13DPredictiveDoes Not SupportResistanceColorectal CancerPanitumumab,CetuximabSartore-Bianchi et al., 2009
CKRASG13DPredictiveSupportsResistanceColorectal CancerPanitumumab,CetuximabSartore-Bianchi et al., 2009
CKRASG12VPredictiveSupportsResistanceColorectal CancerPanitumumab,CetuximabSartore-Bianchi et al., 2009
CVHLc.128-?_250+?PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseLee et al., 2005
Page 83 of 96
PreviousNext